The MSL interview is one of the most demanding in pharma — not because the questions are obscure, but because you're expected to demonstrate scientific credibility, strategic thinking, and interpersonal sophistication at the same time. Novartis, Eli Lilly, BMS, and Genentech run multi-day loops that include journal article critiques, mock KOL meetings, disease state presentations, and deep behavioral interviews.
Here's how to walk in prepared.
What the MSL Interview Is Actually Testing
Hiring managers for MSL roles are asking one underlying question: "Can I send this person to meet a Tier 1 KOL at a major academic medical center, and will they hold their own scientifically and professionally?"
The evaluation covers:
- Scientific depth: Do you know the disease state, clinical data, and competitive landscape?
- KOL strategy: Can you map, prioritize, and engage key opinion leaders?
- Scientific communication: Can you discuss data without selling? Can you critique literature fairly?
- Compliance awareness: Do you understand the boundary between medical and promotional?
- Territory management: Can you run a geography independently?
- Culture fit: MSLs are field-based and largely autonomous — can you thrive without a manager in the room?
The MSL vs Sales Distinction (The Most Common Interview Trap)
Every MSL interview includes some version of this question — explicit or embedded in a scenario:
"What's the difference between an MSL and a sales rep?"
Candidates who blur this line fail. The answer is not "MSLs are more scientific." The answer is structural:
- MSLs are part of Medical Affairs, not Commercial. They report into Chief Medical Officer or VP Medical Affairs structures.
- MSL interactions are non-promotional. They provide balanced, peer-to-peer scientific exchange — including data on competitor products, off-label uses (in response to unsolicited requests only), and pre-approval data.
- Sales reps are governed by promotional materials approved by Med/Legal/Regulatory. MSLs operate on scientific exchange, governed by OIG guidelines, PDMA, and PhRMA Code.
- MSLs do not discuss pricing or access. They do not use approved promotional claims language.
If you're asked to do a mock KOL meeting and you start talking about formulary positioning, patient access, or marketing messages — you've failed the compliance screen.
Round 1: Disease State and Scientific Platform Interview
Most companies send you a disease state and ask you to prepare a scientific platform presentation (typically 20–30 minutes) delivered as if you were in a journal club or KOL advisory board setting.
Format expectations:
- Start with unmet need and disease burden — not mechanism of action
- Cover current standard of care and its limitations
- Present the clinical data for the company's asset: pivotal trial design, endpoints, results (primary + key secondary), safety profile, subgroup analyses
- Acknowledge limitations of the data — not doing so is a red flag
- Cover competitive landscape: what are the alternatives and how does the asset compare?
- End with clinical implications — where does this drug fit in practice?
Dos and don'ts:
- Do cite specific trials by name (KEYNOTE-189, MONARCH-2, POLO, etc.) — knowing trial names signals real depth
- Do present confidence intervals and p-values, not just headline numbers
- Don't present only positive data — acknowledge inconvenient findings and explain them scientifically
- Don't use marketing language ("best-in-class," "superior outcomes") — use clinical language ("statistically significant improvement in PFS at median 18.1 vs 11.4 months, HR 0.61")
The Journal Article Critique
Genentech and BMS are known for giving candidates a published paper — often a Phase 3 trial or meta-analysis — and asking for a critical appraisal. This is usually a 30-minute exercise with questions after.
Framework to use (PICO + bias analysis):
- Population: Is the study population representative of clinical practice? What were the inclusion/exclusion criteria?
- Intervention: What was the treatment, dose, and duration? Is it generalizable?
- Comparator: Was the comparator appropriate? Active control vs placebo?
- Outcomes: Were the endpoints clinically meaningful (OS vs PFS vs ORR vs PK/PD)? Was the primary endpoint pre-specified?
- Bias: Selection bias, performance bias, detection bias, attrition bias, reporting bias
- Statistical: Was the study adequately powered? Was the analysis pre-specified? Multiple comparisons?
- Clinical significance vs statistical significance: A p-value of 0.04 is not useful if the effect size is clinically trivial
Practice this framework with 3–4 papers in the therapeutic area before your interview. Know a landmark trial and a controversial one.
KOL Mapping and Engagement Questions
These test your strategic thinking and field execution:
KOL mapping:
- "How would you identify the top KOLs in your territory for a new cardiology launch?"
- Expected answer: PubMed publication volume and recency, conference presentations and advisory board participation, institutional affiliation (major AMC vs community), guideline committee membership, clinical trial PI activity, referral network centrality
KOL tiering:
- Tier 1 (National KOL): publishes heavily, speaks nationally, shapes guidelines — engage for advisory boards, data publications, congress presentations
- Tier 2 (Regional KOL): respected within a region or specialty — engage for regional speaker programs, clinical feedback
- Tier 3 (Emerging/community): in practice but not yet regionally prominent — maintain relationship, track for tier movement
Engagement planning:
- "How do you prepare for a first meeting with a KOL you've never met?"
- Expected answer: Review their publication history, understand their current research interests, identify a scientific exchange topic of genuine interest to them (not just your product), understand their clinical practice and patient population, have a meaningful insight or dataset to share — not just a product monologue
Reactive vs proactive medical information: This distinction matters legally. Proactive MSL communication = you initiate exchange based on approved, balanced scientific content. Reactive = you respond to an unsolicited request from an HCP, including for off-label information. Know your company's SOP boundary and never mix them up in a scenario question.
Behavioral Questions That Actually Matter
MSL behavioral interviews are heavy because the role is relationship-intensive and largely unsupervised:
- "Tell me about a complex scientific concept you had to explain to a non-expert. How did you tailor your communication?"
- "Describe a time you had a difficult conversation with a physician who disagreed with your data. How did you handle it?"
- "Give me an example of a time you had to navigate a compliance gray area in the field. What did you do?"
- "Tell me about a KOL relationship you built from scratch. What was your approach and what was the outcome?"
- "Describe a time you failed to achieve a territory objective. What did you learn?"
The best answers are specific and clinical — they describe a real interaction, a real scientific debate, a real KOL and what they cared about. Vague answers about "building relationships" don't land.
The 30-60-90 Day Plan
Many MSL final rounds require a 30-60-90 day plan presentation. Interviewers use this to evaluate your strategic thinking and self-management:
30 days (Learn):
- Complete all onboarding, medical affairs training, and compliance certification
- Shadow 2–3 senior MSLs in field calls to observe engagement style
- Review complete clinical data package for all pipeline and marketed assets
- Begin territory analysis: identify top-10 KOL targets using available data
60 days (Engage):
- Conduct introductory scientific exchange meetings with Tier 1 KOLs (target: 15–20 meetings)
- Attend at least one regional medical conference relevant to the therapeutic area
- Complete initial KOL tiering and territory mapping; submit to medical director
- Identify 2–3 KOLs interested in advisory board participation or investigator-initiated research
90 days (Execute):
- Have full territory coverage plan in place with KOL engagement calendar
- Identify any medical gaps or unsolicited requests requiring medical information follow-up
- Contribute to field medical insight report for product team
- Set KPI targets for next quarter: meetings, advisory board nominations, congress abstracts
Be specific — mention the therapeutic area, real conference names, real KOL types. Generic 30-60-90 plans are ignored.
Healthcare Compliance Essentials
MSLs must demonstrate compliance fluency. Any sign that you'd blur the medical/commercial line ends the interview:
OIG (Office of Inspector General) guidelines: Prohibit kickbacks, require bona fide services for speaker fees, mandate fair market value compensation for advisory work.
PDMA (Prescription Drug Marketing Act): Governs samples, promotional materials, and HCP interactions.
PhRMA Code on Interactions with Healthcare Professionals: Industry self-regulation on meals, gifts, speaker programs. Know the $150 meal cap and the prohibition on entertainment.
Off-label information: Can only be provided reactively in response to an unsolicited HCP request. Must be balanced, scientific, and followed by formal medical information response. Never proactively introduce off-label uses.
Questions to Ask the Interviewer
These signal strategic thinking:
- "What does success look like for this territory in the first year — and how will it be measured?"
- "What's the relationship between the MSL team and the medical directors? How does field insight flow back to the organization?"
- "What are the biggest scientific debates in this space that KOLs are currently engaged in?"
- "Is the company planning any investigator-initiated research programs in this therapeutic area?"
Company-Specific Notes
Novartis: Heavy emphasis on scientific rigor and data literacy. Expect a detailed journal club exercise. Their loops often include a scientific committee interview with 3–4 MDs.
Eli Lilly: Strong emphasis on KOL strategy and territory management. Expect scenario questions about building a KOL network from zero in a new geography.
BMS: Oncology-heavy. Know their IO portfolio cold — checkpoint inhibitor mechanisms, combination data, biomarker strategies (PD-L1 expression, TMB, MSI-H). Be ready for a competitive landscape deep dive.
Genentech: Known for rigorous scientific interviews and compliance-focused role-play. They will put you in a scenario where a KOL asks for off-label data. Your response to that scenario is heavily weighted.
The MSL role rewards candidates who are genuinely scientifically curious, tactful enough to engage expert clinicians as peers, and disciplined enough to stay on the right side of medical/commercial boundaries. Show all three and you'll stand out.
Simulate real MSL interview scenarios with AI-powered practice at CareerLift.ai.